Amoeba SA (FR:ALMIB)
:ALMIB
ALMIB Stock Chart & Stats
€1.08
-€0.01(-1.20%)
At close: 4:00 PM EST
€1.08
-€0.01(-1.20%)
Day’s Range― - ―
52-Week Range€0.78 - €1.44
Previous CloseN/A
Volume10.38K
Average Volume (3M)268.33K
Market Cap
€65.42M
Enterprise Value€65.45M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.95
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.14
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Biological PlatformOwning a proprietary microorganism provides a durable technical moat: unique biological IP can enable differentiated product claims versus chemical treatments, lengthen commercialization timelines for competitors, and support regulatory dossiers and licensing opportunities across ag and industrial markets.
Multiple End-market ApplicationsServing both agricultural biocontrol/biostimulant and industrial water-treatment markets reduces single-market dependency. This structural diversification creates multiple commercialization pathways, spreads development risk and allows cross-market learning to support steady revenue rebuilding.
Recent Free Cash Flow ImprovementAn improvement in free cash flow versus the prior year signals early progress on cash conversion and cost control. While still negative, a durable trend of improving FCF would reduce near-term funding needs and lower refinancing frequency if sustained over the next several quarters.
Bears Say
Revenue Collapse In 2025A full-year revenue collapse erodes scale economics and raises questions on commercial traction and market adoption. Without recurring top-line, fixed-cost absorption, regression to profitable margins is unlikely and recovery will require successful re-commercialization or new revenue streams.
Consistent Negative Cash GenerationPersistent negative operating cash flow forces reliance on external financing and dilutive funding events. Continued cash burn constrains R&D and commercialization investment, increases refinancing risk, and can impair long-term survival absent clear and sustained cash-flow improvement.
Negative Equity And Rising DebtNegative equity and materially higher leverage impair financial flexibility and increase default/refinancing risk. This capital structure limits the company's ability to withstand shocks, raises cost of capital, and may constrain strategic choices such as partnerships or commercial scaling.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.78 and its highest was €1.44 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €65.42M.
When is Amoeba SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Amoeba SA’s earnings last quarter?
Currently, no data Available
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protection. The company was founded in 2010 and is headquartered in Chassieu, France.
Technical Analysis
Options Prices
Currently, No data available
---